by admin | Apr 19, 2024 | Article
On April 14, Evusheld – the only pre-exposure long-acting monoclonal antibody for COVID-19 prevention – was authorized by Health Canada and recently supported with broad recommendations for use in immune-compromised Canadians by the Canadian Agency...
by admin | Apr 19, 2024 | Article
The Phase III Tulip trial on Anifrolumab (a monoclonal antibody that blocks type 1 interferons) evaluated the efficacy and safety of anifrolumab in autoantibody-positive SLE who are receiving standard of care. Besides meeting the primary endpoint, the Tulip 2 trial...
by admin | Apr 19, 2024 | Article
Lupus Canada proudly supports Dr. Barraclough and Dr. Touma’s study, Cognitive Dysfunction and Fatigue in Systemic Lupus Erythematosus, through our 2021 Catalyst Grant. To learn more about the grant recipients and their project please...
by admin | Apr 19, 2024 | Article
The COVID-19 pandemic presents a natural experiment for researchers to discern how lupus patients access, use and trust advocacy organizations. A research team from Calgary, Waterloo, and global lupus clinicians and advocacy organizations undertook an (inter)national...
by admin | Apr 19, 2024 | Article
UM clinician scientist Dr. Lily Lim is using artificial intelligence (AI) to better recognize lupus in patients. Known as “the disease with a thousand faces” symptoms vary from person to person. Lab tests aren’t always conclusive. The autoimmune disorder is infamously...
by admin | Apr 19, 2024 | Article
In a new study, researchers explored predictors of neuropsychiatric (brain-related) flare activity in people with lupus being treated with active disease (without ongoing or severe neuropsychiatric involvement), and found an association...
